<DOC>
	<DOC>NCT03004833</DOC>
	<brief_summary>The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.</brief_summary>
	<brief_title>Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically proven classical HL First diagnosis, no previous treatment Age: 1860 years Stage I, IIA with risk factors ad, IIB with RF cd: 1. large mediastinal mass 2. extranodal lesions 3. elevated ESR 4. ≥ 3 nodal areas confirmed by central review. Composite lymphoma or nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) History of other malignancy ≤ 5 years Prior chemotherapy or radiation therapy Concurrent disease precluding protocol treatment Pregnancy, lactation Noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>